- Home
- UNCY vs ANVS Comparison
UNCY vs ANVS Comparison
Compare UNCY & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | ANVS |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.9M | 111.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UNCY | ANVS |
|---|---|---|
| Price | $5.88 | $3.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $44.50 | $13.50 |
| AVG Volume (30 Days) | 394.5K | ★ 4.0M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $1.11 |
| 52 Week High | $11.00 | $6.37 |
Technical Indicators
Market Signals| Indicator | UNCY | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 52.44 |
| Support Level | $6.31 | $4.12 |
| Resistance Level | $6.95 | $4.24 |
| Average True Range (ATR) | 0.42 | 0.47 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 13.06 | 11.67 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.